TABLE 3.
Surface marker | AhR+/+ |
AhR−/− |
||||
DMSO | I3C | IO | DMSO | I3C | IO | |
CD11c | 3391 ± 142 | 2603 ± 326* | 2219 ± 312* | 4611 ± 548 | 4822 ± 107 | 3992 ± 280 |
MHC2 | 2833 ± 81 | 8056 ± 400* | 6432 ± 255* | 1970 ± 100 | 2912 ± 125* | 2067 ± 100 |
CD86 | 1299 ± 15 | 1493 ± 3* | 1270 ± 10 | 1279 ± 5 | 950 ± 27* | 1180 ± 31* |
CD80 | 1176 ± 23 | 1901 ± 8* | 1412 ± 8* | 839 ± 14 | 1129 ± 14* | 822 ± 13 |
CD54 | 548 ± 7 | 507 ± 11* | 435 ± 6* | 649 ± 6 | 630 ± 12 | 633 ± 10 |
CD40 | 334 ± 72 | 290 ± 11* | 291 ± 5* | 409 ± 18 | 308 ± 16* | 358 ± 6* |
AhR+/+ and AhR−/− BMDCs were grown in the presence of vehicle, 50μM I3C or 1μM IO and subsequently immunophenotyped prior to LPS stimulation. Mean fluorescence intensity values are shown as mean ± standard error. Data are representative of two independent experiments with n = 3.
*Significance of p ≤ 0.05 compared with DMSO control of respective cell type.